Q3 EPS Estimates for Cabaletta Bio Raised by HC Wainwright

Cabaletta Bio, Inc. (NASDAQ:CABA) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings estimates for shares of Cabaletta Bio in a report issued on Friday, August 14th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.36). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.35) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.33) EPS, FY2027 earnings at ($1.29) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at $0.89 EPS.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03.

Several other analysts have also recently issued reports on CABA. Wall Street Zen cut Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of Cabaletta Bio in a report on Monday, May 4th. Wells Fargo & Company lowered their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.33.

Cabaletta Bio Stock Performance

Shares of Cabaletta Bio stock opened at $2.89 on Tuesday. Cabaletta Bio has a one year low of $1.40 and a one year high of $4.23. The company has a market cap of $471.23 million, a price-to-earnings ratio of -1.84 and a beta of 3.30. The business’s 50 day moving average price is $2.88 and its 200 day moving average price is $3.06.

Institutional Investors Weigh In On Cabaletta Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Cabaletta Bio during the 2nd quarter worth $33,447,000. T. Rowe Price Investment Management Inc. raised its holdings in Cabaletta Bio by 17.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock valued at $21,590,000 after buying an additional 1,495,768 shares during the period. Jennison Associates LLC lifted its position in Cabaletta Bio by 0.7% in the first quarter. Jennison Associates LLC now owns 8,970,578 shares of the company’s stock valued at $24,131,000 after buying an additional 64,879 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after buying an additional 5,195,285 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Cabaletta Bio by 21.4% during the third quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after buying an additional 740,032 shares during the period.

Cabaletta Bio News Summary

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Cabaletta Bio’s third and fourth quarters of 2026 to approximately $(0.31) from $(0.36), and increased its full-year 2026 loss estimate to $(1.35) from $(1.51). The firm also reduced projected losses for 2027 and 2028, including raising FY2027 EPS to $(1.29) from $(1.48) and FY2028 EPS to $(0.74) from $(1.41). These revisions suggest improving expectations for the company’s cost structure or cash runway.
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Cabaletta Bio to remain unprofitable through 2029, with a forecasted return to positive EPS of $0.89 in 2030. The current-year consensus remains a loss of approximately $(1.34) per share, highlighting the stock’s dependence on clinical and commercial progress rather than near-term earnings.
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to $(0.68) from $(0.64) and its FY2030 forecast to $0.89 from $1.11. These cuts temper the benefit of the earlier-year estimate increases and imply a slower long-term earnings trajectory.
• Negative Sentiment: Wells Fargo cut its Cabaletta Bio price target to $3.00. With the shares recently near $2.89, the revised target indicates limited near-term upside and may weigh on investor sentiment. Wells Fargo Cuts Cabaletta Bio Price Target

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.